People · Operator
Named in public records as an officer, director or promoter · active 2019–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Summit Therapeutics Inc. | — | Biotechnology | Series D+ | $569.0M | $2.4B | 2019 |
| Juvenescence Ltd | — | Biotechnology | Series C | $121.9M | $324.3M | 2020 |
| Relation Therapeutics Inc. | — | Biotechnology | Series C | $116.4M | $189.7M | 2021 |
David Roblin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Roblin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jim Mellon | 2 | 4 |
| Jeff Huber | 1 | 75 |
| James Mellon | 1 | 10 |
| Mostafa Ronaghi | 1 | 8 |
| Gregory Bailey | 1 | 8 |
| David Wurzer | 1 | 7 |
| Declan Doogan | 1 | 6 |
| Jason Pontin | 1 | 5 |
| Charles Roberts | 1 | 4 |
| Christine Aylward | 1 | 4 |
| Denham Eke | 1 | 4 |
| Robert Booth | 1 | 4 |
| Mahkam Zanganeh | 1 | 3 |
| Robert Duggan | 1 | 3 |
| Raymond Spencer | 1 | 3 |
| Kenneth Clark | 1 | 3 |
| Barry Price | 1 | 2 |
| Leopoldo Zambeletti | 1 | 2 |
| Colin Watts | 1 | 2 |
| Manmeet Soni | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.